ClinicalTrials.gg
Status unknownNCT05151055Updated Dec 9, 2021

Lactoferrin + Vitamin E + Zinc for Hormonal Acne

A Phase 2 interventional study of Lactezin and Placebo in Hormonal Acne, sponsored by United Laboratories. Status unknown at 1 site in Philippines. Open to female participants aged 22 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-09.

Sponsored by United Laboratories · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Mar 2020, registered Nov 2021).
Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
22 Years to 50 Years
Sex
Female
01

Study summary

We previously showed that twice daily intake of a combination of 100 mg lactoferrin, 11 IU vitamin E, and 5 mg zinc significantly reduced both inflammatory and non-inflammatory acne lesions compared to placebo control. In that study, females showed an overall better response compared to males in terms of total lesions. We speculated that the gender effect may be due to mitigation of the pre- menstrual flare-ups women have that lead to recurring acne, making them have a better response. The objectives of this study are: 1.) to characterize the efficacy and safety of 100 mg lactoferrin + 11 IU vitamin E + 5 mg zinc in the adult female population who suffer from hormonal acne, 2.) to determine whether the anti-acne effect is maintained after treatment stops.

02

Conditions studied

  • Hormonal Acne
03

In context

Lead sponsor

United Laboratories is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 22-50.
  2. At least 3 inflammatory acne lesions, mostly found on (but not limited to) the lower face
  3. Not responsive to conventional treatment
  4. Clinical diagnosis of mild to moderate acne according to Lehmann et. al.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant (confirmed by a pregnancy test), breast- feeding, or planning a pregnancy.
  2. women
  3. Current or recent (within 3 months) use of any topical or oral anti- acne products,
  4. Hormonal intake in the preceding six months
  5. A cancer diagnosis within the past 5 years
  6. History of to any component of the test product.
  7. Current imuunosuppression. Specifically, these include patients with co-morbidities such as diabetes, , chronic diseases patients requiring maintenance medications, such as vascular disease,

    • hepatitis, eczema, psoriasis, or acute febrile/infectious illnesses
    • (i.e. Dengue, pneumonia, etc)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Lactezin

    100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)

    Dietary Supplement: Lactezin

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLactezin

    100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)

  • Dietary supplementPlacebo

    starch

06

What researchers measure

Primary outcomes

  1. Mean percentage change in inflammatory acne lesions at 2, 4, 6, 8, 10, and 12 weeks compared to baseline, in the treatment versus placebo groups

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage change in inflammatory acne lesion counts at 14, 16, 18, 20, 22, and 24 weeks compared to baseline

    Time frame: 24 weeks

  2. Mean percent change in the AFAST scores at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 weeks compared to baseline, in the treatment versus placebo groups

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Clinical Trial Management and Testing Associates, Inc.
    Muntinlupa, Philippines
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Jun 2022, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2021
First posted
Dec 9, 2021
StartActual
Mar 2, 2020
Primary completionEst.
Jun 2022
CompletionEst.
Sep 2022
Last update
Dec 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05151055
Lead sponsor
United Laboratories
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Mar 2, 2020
Primary completion
Jun 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Dec 9, 2021

Study contacts

Juliene Lim, Ph.D.
Contact
jgco@unilab.com.ph
63288581000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion